As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Agomab Therapeutics NV. The largest reported stake is LSP 7 Cooperatieve U.A.'s, at 10.6%. 6 filings are on record since February 17, 2026 (Schedule 13D, February 17, 2026).
Who owns Agomab Therapeutics NV?
Sell to companies like Agomab Therapeutics NV? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Redmile Group, LLC · Percent: 5.6% · SCHEDULE 13G
- · Holder: Cormorant Asset Management, LP · Percent: 5.01% · SCHEDULE 13G
- · Holder: Sanofi · Percent: 5.71% · SCHEDULE 13G
- · Holder: Pontifax VI G.P. L.P. · Percent: 6.8% · SCHEDULE 13G
- · Holder: Fmr LLC · Percent: 10% · SCHEDULE 13G
Agomab Therapeutics NV has 6 Schedule 13D or 13G filings on record since 2026-02-17. 6 holders' latest filing reports 5% or more of american depositary shares, each representing one common share, no nominal value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. | 10.6% | 5,141,992 | SCHEDULE 13D, 2026-02-17 | 2026-02-09 |
| Fmr LLC | 10% | 4,873,680 | SCHEDULE 13G, 2026-03-06 | 2026-02-27 |
| Pontifax VI G.P. L.P. | 6.8% | 3,305,846 | SCHEDULE 13G, 2026-04-16 | 2026-03-31 |
| Sanofi | 5.71% | 2,783,096 | SCHEDULE 13G, 2026-05-06 | 2026-03-31 |
| Redmile Group, LLC | 5.6% | 2,735,926 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Cormorant Asset Management, LP | 5.01% | 2,465,348 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Agomab Therapeutics NV and the warning signs.
Free to see. No signup.
Keep reading
More on Agomab Therapeutics NV and the records around it.
Agomab Therapeutics NV elsewhere on the record
Companies that share a holder
- LSP 7 Cooperatieve U.A. also filed stake reports on 3 other companies: Electra Therapeutics, Inc. (Sep 2026), Oculis Holding AG (Apr 2026), Evommune, Inc. (Feb 2026)
- Pontifax VI G.P. L.P. also filed stake reports on 3 other companies: Keros Therapeutics, Inc. (Oct 2025), LB Pharmaceuticals Inc (Sep 2025), Climb Bio, Inc. (Sep 2025)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Corbus Pharmaceuticals Holdings, Inc. (Nov 2026), Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026)
Watch Agomab Therapeutics NV
Get an email when Agomab Therapeutics NV files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Agomab Therapeutics NV?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Agomab Therapeutics NV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Agomab Therapeutics NV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
LSP 7 Cooperatieve U.A.
Amended and Restated Shareholders' Agreement On November 4, 2024, certain shareholders of the Issuer, including LSP 7, entered into an amended and restated shareholders' agreement (the "Shareholders' Agreement") with the Issuer, pursuant to which the Issuer agreed, among other things, to register for resale certain Common Shares and other equity securities of the Issuer that are held by the parties (the "Registrable Securities"), and agreed to provide customary demand and "piggyback" registration rights, subject to certain requirements and conditions. The Shareholders' Agreement terminated immediately prior to the consummation of the IPO, except for the confidentiality provisions and registration rights granted thereunder. The registration rights granted under the Shareholders' Agreement will terminate upon the earlier of upon the earliest of one of the following three events: (1) a liquidity event, such as payment of dividends or a share buy-back, a bankruptcy or similar liquidation or dissolution, an asset sale or any merger or consolidation or acquisition of the Issuer; (2) such time as Rule 144 or another similar exemption under the Securities Act of 1933, as amended, is available for the sale of all of such holder's shares without limitation (including without observance of the manner of sale, volume limitation and notice provisions of Rule 144) during a three month period without registration; and (3) the third anniversary of the IPO. Lock-up Agreement In …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-17; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-02-17 | LSP 7 Cooperatieve U.A. | 10.6% | SCHEDULE 13D |
| 2026-03-06 | Fmr LLC | 10% | SCHEDULE 13G |
| 2026-04-16 | Pontifax VI G.P. L.P. | 6.8% | SCHEDULE 13G |
| 2026-05-06 | Sanofi | 5.71% | SCHEDULE 13G |
| 2026-05-15 | Redmile Group, LLC | 5.6% | SCHEDULE 13G |
| 2026-05-15 | Cormorant Asset Management, LP | 5.01% | SCHEDULE 13G |
Questions about who owns Agomab Therapeutics NV
Who owns Agomab Therapeutics NV?
On this page, 6 holders' latest ownership filings report 5% or more of Agomab Therapeutics NV: LSP 7 Cooperatieve U.A. (10.6%, Schedule 13D, filed 2026-02-17), Fmr LLC (10%, Schedule 13G, filed 2026-03-06), Pontifax VI G.P. L.P. (6.8%, Schedule 13G, filed 2026-04-16), Sanofi (5.71%, Schedule 13G, filed 2026-05-06) and Redmile Group, LLC (5.6%, Schedule 13G, filed 2026-05-15); 1 more is listed above.
Who are the largest shareholders of Agomab Therapeutics NV?
By the share each holder's latest filing reports, the largest holders of Agomab Therapeutics NV on this page are LSP 7 Cooperatieve U.A. (10.6%), Fmr LLC (10%) and Pontifax VI G.P. L.P. (6.8%).
When did LSP 7 Cooperatieve U.A. buy into Agomab Therapeutics NV?
The filings give report dates, not purchase dates. The earliest filing from LSP 7 Cooperatieve U.A. on this page is the Schedule 13D, filed 2026-02-17, reporting 10.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Agomab Therapeutics NV
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 6, 2026 | IPO filing, Form 424B4 | $16 a share | IPO filings | Source |
| January 29, 2026 | IPO filing, Form F-1/A | $15 to $17 a share | IPO filings | Source |
| January 16, 2026 | IPO filing, Form F-1 | — | IPO filings | Source |
Tools for this story
Each opens in a new tab, filled in for Agomab Therapeutics NV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.